ILE Isolagen

EXTON, Pa., June 19 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today that it intends to reschedule its 2006 annual meeting of stockholders originally scheduled for June 21, 2006. As previously announced, the company has recently appointed Nicholas L. Teti as Chairman and CEO, as well as Declan Daly as CFO and Executive Vice President and Steven Trider as Senior Vice President, and these new officers are in the process of transitioning into the company. Isolagen will announce a new meeting date and record date for stockholders eligible to vote at the meeting shortly. About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com/ . DATASOURCE: Isolagen, Inc. CONTACT: investors, Lee M. Stern of The Trout Group, +1-212-477-9007, or ; or media, Mike Beyer of Sam Brown Inc., +1-773-463-4211, or , both for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright